Kardigan KARD
NASDAQ KARD
$13.82 -0.30 (-2.12%)
At close: Nov 13, 2026 · 4:00 PM EST

Kardigan (KARD) Sale and Maturity of Investments (2026)

Updated

Kardigan (KARD) recorded Sale and Maturity of Investments - Total of $91.75 million in Q3 2026.

Analysis

Kardigan (KARD) Sale and Maturity of Investments (2026) Analysis & Trends

For FY2025, Kardigan reported Sale and Maturity of Investments - Total of $17 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Investments Sold (Qtr)
1 Eli Lilly 1,359.75 Bn 1,333.37 Bn 20.46 Bn -
2 Johnson & Johnson 688.76 Bn 608.62 Bn 17.30 Bn 308.00 Mn
3 AbbVie 521.69 Bn 489.75 Bn 13.12 Bn -
4 Merck 364.31 Bn 327.31 Bn 13.19 Bn 405.00 Mn
5 Novartis Ag 306.35 Bn 279.93 Bn - 88.00 Mn
6 Astrazeneca 285.96 Bn 259.56 Bn 13.26 Bn -
7 Amgen 251.88 Bn 203.53 Bn 7.58 Bn -
8 Gilead Sciences 208.59 Bn 183.61 Bn 6.73 Bn -
9 Pfizer 164.73 Bn 112.38 Bn 12.56 Bn 2.53 Bn
10 Kardigan 1.29 Bn -398.44 Mn - 91.75 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 91.75 Mn
Mar 31, 2026 79.35 Mn
API Access

Kardigan Sale and Maturity of Investments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=sale-and-maturity-of-investments&ticker=KARD&period=max&api_key=YOUR_API_KEY